Karsten Müssig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Karsten Müssig has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Baptist Gallwitz
2 shared publicationsHans-Ulrich Häring
2 shared publicationsRalf Saur
2 shared publicationsStefan Klingberg
2 shared publicationsThomas Leyhe
2 shared publicationsAndreas Künle
1 shared publication
Latest Publications
- 1 May 2012
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 26 (4) , 559-563
Thyroid peroxidase antibody positivity is associated with symptomatic distress in patients with Hashimoto’s thyroiditis
- 1 May 2012
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 26 (4) , 559-563
Thyroid peroxidase antibody positivity is associated with symptomatic distress in patients with Hashimoto’s thyroiditis
- 16 January 2012
- Published by Wiley in Clinical Endocrinology
- Vol. 77 (1) , 139-145
Expression of the proliferation marker Ki‐67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas
Summary: Objective: Although the prognosis of differentiated thyroid carcinoma (DTC) is excellent, with 10‐year survival rates of about 90%, about one‐third of patients experiences recurrent disease. We aimed to identify novel histological prognostic factors to optimize treatment and follow‐up of patients at risks.Design: Retrospective analysis of patients diagnosed from January 1990 to March 2004.Subjects: A total of 93 patients diagnosed with DTC of which 67 with papillary and 26 with follicular histology.Measurements: Analysis of immunohistochemical expression of somatostatin receptor (sst) subtypes 1–5, glucose transporter‐1 (GLUT‐1), receptor tyrosine kinase c‐KIT, oestrogen and progesterone receptors, and proliferation marker Ki‐67 and correlation with the patients’ clinical outcome.Results: DTC showed immunohistochemical expression of GLUT‐1, C‐KIT and progesterone receptor in a high percentage of cases (range: 57–80%). In contrast, the oestrogen receptor as well as the sst subtypes 1–5 was less frequently detected (range: 15–29%). Mean staining of the proliferation marker Ki‐67 was 6% positive cells (range 0–20%). Ki‐67 expression was significantly associated with tumour staging (ρ = 0·2076, P = 0·0459), whereas the other histopathological markers were not associated with gender, age, tumour entity, or tumour classification. Tumour staging and expression of Ki‐67, oestrogen receptor and sst2, but of none of the other histopathological factors, independently predicted the clinical outcome 5 years after definitive treatment (P < 0·0001, P < 0·0001, P = 0·0004 and P = 0·0206, respectively).Conclusions: In patients with DTC, Ki‐67 expression associates with tumour staging and clinical outcome.
- 16 January 2012
- Published by Wiley in Clinical Endocrinology
- Vol. 77 (1) , 139-145
Expression of the proliferation marker Ki‐67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas
Summary: Objective: Although the prognosis of differentiated thyroid carcinoma (DTC) is excellent, with 10‐year survival rates of about 90%, about one‐third of patients experiences recurrent disease. We aimed to identify novel histological prognostic factors to optimize treatment and follow‐up of patients at risks.Design: Retrospective analysis of patients diagnosed from January 1990 to March 2004.Subjects: A total of 93 patients diagnosed with DTC of which 67 with papillary and 26 with follicular histology.Measurements: Analysis of immunohistochemical expression of somatostatin receptor (sst) subtypes 1–5, glucose transporter‐1 (GLUT‐1), receptor tyrosine kinase c‐KIT, oestrogen and progesterone receptors, and proliferation marker Ki‐67 and correlation with the patients’ clinical outcome.Results: DTC showed immunohistochemical expression of GLUT‐1, C‐KIT and progesterone receptor in a high percentage of cases (range: 57–80%). In contrast, the oestrogen receptor as well as the sst subtypes 1–5 was less frequently detected (range: 15–29%). Mean staining of the proliferation marker Ki‐67 was 6% positive cells (range 0–20%). Ki‐67 expression was significantly associated with tumour staging (ρ = 0·2076, P = 0·0459), whereas the other histopathological markers were not associated with gender, age, tumour entity, or tumour classification. Tumour staging and expression of Ki‐67, oestrogen receptor and sst2, but of none of the other histopathological factors, independently predicted the clinical outcome 5 years after definitive treatment (P < 0·0001, P < 0·0001, P = 0·0004 and P = 0·0206, respectively).Conclusions: In patients with DTC, Ki‐67 expression associates with tumour staging and clinical outcome.
- 21 December 2010
- Published by Cambridge University Press (CUP) in Journal of the International Neuropsychological Society
- Vol. 17 (2) , 369-375
Deteriorated Executive Functions in Patients with Successful Surgery for Pituitary Adenomas Compared with Other Chronically Ill Patients
Pituitary adenomas, even after successful treatment, are associated with cognitive impairments. It is unclear whether these deficits are a consequence of unspecific factors associated with having a chronic illness and whether the cognitive dysfunctions exceed those of other chronically ill patients. Thirty-eight patients with transsphenoidal surgery for pituitary adenomas and 38 patients undergoing L-thyroxine replacement therapy after thyroid surgery were studied neuropsychologically with established tests. Executive function was examined with the Trail-Making Test A and B, working memory with the digit span test, attention with the digit symbol test, verbal memory with the German version of the Auditory Verbal Learning and Memory Test, and general verbal intelligence by a vocabulary test. Attention (p = .007), attentional speed (p = .0004), executive control (p = .04), and working memory (p = .01), were significantly reduced in patients with pituitary adenomas compared with other chronically ill patients. In contrast, no differences were found between the groups for verbal memory (all subtests: p ≥ .06). Patients with successful surgery for pituitary adenomas show also in comparison with other chronically ill patients an increased risk for deficits in certain aspects of cognitive function, including attention and working memory, supporting the relevance of the brain lesion and its treatment for these dysfunctions. (JINS, 2011, 17, 369–375)
- 21 December 2010
- Published by Cambridge University Press (CUP) in Journal of the International Neuropsychological Society
- Vol. 17 (2) , 369-375
Deteriorated Executive Functions in Patients with Successful Surgery for Pituitary Adenomas Compared with Other Chronically Ill Patients
Pituitary adenomas, even after successful treatment, are associated with cognitive impairments. It is unclear whether these deficits are a consequence of unspecific factors associated with having a chronic illness and whether the cognitive dysfunctions exceed those of other chronically ill patients. Thirty-eight patients with transsphenoidal surgery for pituitary adenomas and 38 patients undergoing L-thyroxine replacement therapy after thyroid surgery were studied neuropsychologically with established tests. Executive function was examined with the Trail-Making Test A and B, working memory with the digit span test, attention with the digit symbol test, verbal memory with the German version of the Auditory Verbal Learning and Memory Test, and general verbal intelligence by a vocabulary test. Attention (p = .007), attentional speed (p = .0004), executive control (p = .04), and working memory (p = .01), were significantly reduced in patients with pituitary adenomas compared with other chronically ill patients. In contrast, no differences were found between the groups for verbal memory (all subtests: p ≥ .06). Patients with successful surgery for pituitary adenomas show also in comparison with other chronically ill patients an increased risk for deficits in certain aspects of cognitive function, including attention and working memory, supporting the relevance of the brain lesion and its treatment for these dysfunctions. (JINS, 2011, 17, 369–375)
- 9 November 2010
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 135 (46) , 2309-2310
52-jährige Patientin mit flüchtigem Exanthem, Fieber und Arthralgien
Die 52-jährige Patientin wurde wegen seit sechs Wochen bestehender schmerzhafter Schwellungen der proximalen Interphalangealgelenke der Finger, der Ellenbogen und der Handgelenke sowie wegen intermittierender abendlicher Temperaturanstiege bis 40 °C stationär aufgenommen. In engem zeitlichem Zusammenhang mit den Fieberspitzen trat das in der Abbildung gezeigte flüchtige Exanthem am rechten Oberarm auf. Die Untersuchung der Patientin ergab einen pathologischen Befund Welcher ist das? Erlaubt dieser Befund eine Diagnose? Wenn ja, welche? Sind Differenzialdiagnosen möglich? Wenn ja, welche? Auflösung
- 9 November 2010
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 135 (46) , 2309-2310
52-jährige Patientin mit flüchtigem Exanthem, Fieber und Arthralgien
Die 52-jährige Patientin wurde wegen seit sechs Wochen bestehender schmerzhafter Schwellungen der proximalen Interphalangealgelenke der Finger, der Ellenbogen und der Handgelenke sowie wegen intermittierender abendlicher Temperaturanstiege bis 40 °C stationär aufgenommen. In engem zeitlichem Zusammenhang mit den Fieberspitzen trat das in der Abbildung gezeigte flüchtige Exanthem am rechten Oberarm auf. Die Untersuchung der Patientin ergab einen pathologischen Befund Welcher ist das? Erlaubt dieser Befund eine Diagnose? Wenn ja, welche? Sind Differenzialdiagnosen möglich? Wenn ja, welche? Auflösung